Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Geoffrey Kuesters"'
Autor:
Hanna Huebner, Christian M. Kurbacher, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens Huober, Bernhard Volz, Florin-Andrei Taran, Friedrich Overkamp, Hans Tesch, Lothar Häberle, Diana Lüftner, Markus Wallwiener, Volkmar Müller, Matthias W. Beckmann, Erik Belleville, Matthias Ruebner, Michael Untch, Peter A. Fasching, Wolfgang Janni, Tanja N. Fehm, Hans-Christian Kolberg, Diethelm Wallwiener, Sara Y. Brucker, Andreas Schneeweiss, Johannes Ettl
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
Abstract Background Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. Howe
Externí odkaz:
https://doaj.org/article/3595f6bd2f1948ae89b5ca12ff495d0f
Autor:
Francesca De Bacco, Francesca Orzan, Jessica Erriquez, Elena Casanova, Ludovic Barault, Raffaella Albano, Antonio D’Ambrosio, Viola Bigatto, Gigliola Reato, Monica Patanè, Bianca Pollo, Geoffrey Kuesters, Carmine Dell’Aglio, Laura Casorzo, Serena Pellegatta, Gaetano Finocchiaro, Paolo M. Comoglio, Carla Boccaccio
Publikováno v:
Cell Reports, Vol 36, Iss 4, Pp 109455- (2021)
Summary: In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted
Externí odkaz:
https://doaj.org/article/e9b83391a07f492884f43b9f386fe11c
Autor:
Lia Luus, Vasileios Askoxylakis, John Wilton, Alexey Lugovskoy, Kenneth J. Olivier, Stephanie Grabow, Jaeyeon Kim, Christine Pien, Geoffrey Kuesters, Suresh K. Tipparaju, Melissa Geddie, Nancy Dumont, Mark E. Hayes, Alexander Koshkaryev, Sarah A Schihl, C. Patrick Reynolds, Rachel Blaydes, Andrew J. Sawyer, James D. Marks, Tad Kornaga, James Suchy, Charles O. Noble, Dmitri B. Kirpotin, Shinji Oyama, Neeraj Kohli, Zhaohua Richard Huang, Walid S. Kamoun, Daryl C. Drummond, Yu Zhou
Publikováno v:
Nature Biomedical Engineering. 3:264-280
Antibody-mediated tumour targeting and nanoparticle-mediated encapsulation can reduce the toxicity of antitumour drugs and improve their efficacy. Here, we describe the performance of a nanotherapeutic encapsulating a hydrolytically sensitive docetax
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d8e94f819de7e7f6ccdf49b01d0fee2
https://doi.org/10.1038/s41551-019-0385-4
https://doi.org/10.1038/s41551-019-0385-4
Autor:
Gigliola Reato, Carmine Dell'Aglio, Serena Pellegatta, Laura Casorzo, Monica Patanè, Geoffrey Kuesters, Bianca Pollo, G. Finocchiaro, Raffaella Albano, Francesca Orzan, Elena Casanova, Francesca De Bacco, Antonio D'Ambrosio, Viola Bigatto, Carla Boccaccio, Paolo M. Comoglio, Ludovic Barault, Jessica Erriquez
Publikováno v:
Cell Reports, Vol 36, Iss 4, Pp 109455-(2021)
Summary In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71490ed6a4f68d953fba7cb26eb5eb77
http://hdl.handle.net/2318/1795377
http://hdl.handle.net/2318/1795377
Population Pharmacokinetics and Target Engagement of Natalizumab in Patients With Multiple Sclerosis
Autor:
Tatiana Plavina, Kumar Kandadi Muralidharan, Daniel Mikol, Meena Subramanyam, Sreeja Gopal, Geoffrey Kuesters, Ivan Nestorov
Publikováno v:
The Journal of Clinical Pharmacology. 57:1017-1030
Natalizumab (humanized immunoglobulin G4 antibody targeting alpha-4 integrins) is a highly efficacious treatment for relapsing-remitting multiple sclerosis (RRMS) that has been in clinical use since 2006. However, natalizumab pharmacokinetic (PK) cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65ebc40abe1d445c88c2c45f80123e38
https://doi.org/10.1002/jcph.894
https://doi.org/10.1002/jcph.894
Autor:
Christopher Plescia, Karen Campbell, Tiffany Chen, Ramez N. Eskander, Alexander I. Spira, Ezra E.W. Cohen, Johanna C. Bendell, Geoffrey Kuesters, Omid Hamid
Publikováno v:
Journal of Clinical Oncology. 39:TPS2664-TPS2664
TPS2664 Background: High-risk strains of HPV (HPV 16/18) have been associated with the development of multiple cancers, and the associated viral antigens are validated targets from immunotherapy approaches. We engineered red blood cells into allogene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa4b1a2b7296c8e71d8d3d65b1110e74
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2664
https://doi.org/10.1200/jco.2021.39.15_suppl.tps2664
Autor:
Douglas Donaldson, Alvydas Mikulskis, David Yeung, Chase Shen, Shobha Purushothama, Shawn Ciotti, Geoffrey Kuesters, Brian Schlain, Elham Gharakhani
Publikováno v:
Journal of Immunological Methods. 437:53-63
A comprehensive cross-platform and cross-assay evaluation using nine technology platforms and four cytokine immunoassays (IL-6, TNFα, IL-17a, IL-2) was performed by comparing assay precision, sensitivity, parallelism and data correlation between pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::614d5bf9daf9709190b093018d27b9c4
https://doi.org/10.1016/j.jim.2016.08.003
https://doi.org/10.1016/j.jim.2016.08.003
Autor:
Manuel Modiano, Bambang Adiwijaya, Frances A. Shepherd, Walid S. Kamoun, Enriqueta Felip, Sergio Santillana, Wael A. Harb, Lecia V. Sequist, Maria Q. Baggstrom, M. Cobo, Ariel Lopez-Chavez, Akin Atmaca, Geoffrey Kuesters, Mariano Provencio, Keunchil Park, J. Marc Pipas, Jhanelle E. Gray, Robert C. Doebele, David M. Jackman, Karen Andreas, Byoung Chul Cho
Publikováno v:
The oncologist. 24(8)
BACKGROUND. Seribantumab (MM‐121) is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3/ErbB3) to block heregulin (HRG/NRG)‐mediated ErbB3 signaling and induce receptor downregulation. This open‐
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59a753e0a0aee9847626ec9b72494598
https://pubmed.ncbi.nlm.nih.gov/30975923
https://pubmed.ncbi.nlm.nih.gov/30975923
Autor:
Robin Caputo, Ellen Rohde, Geoffrey Kuesters, Luisette Delva, Tonika Bohnert, Paul H. Weinreb, Qin Wang, Elvana Veizaj, Weiping Chen, Liang-Shang Gan, R. B. Pepinsky, Danielle Graham, Ivan Nestorov, Anne Cheung
Publikováno v:
Fluids and Barriers of the CNS
Fluids and Barriers of the CNS, Vol 15, Iss 1, Pp 1-10 (2018)
Fluids and Barriers of the CNS, Vol 15, Iss 1, Pp 1-10 (2018)
Many studies have focused on the challenges of small molecule uptake across the blood–brain barrier, whereas few in-depth studies have assessed the challenges with the uptake of antibodies into the central nervous system (CNS). In drug development,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5055777cf9a0d843df8f75e56618a1c
https://pubmed.ncbi.nlm.nih.gov/29558954
https://pubmed.ncbi.nlm.nih.gov/29558954
Autor:
Jhanelle E. Gray, Enriqueta Felip, Pasi A. Jänne, Lecia V. Sequist, Fred R. Hirsch, Daniel Shao-Weng Tan, Geoffrey Kuesters, Alena Zalutskaya, Frances A. Shepherd, Rudolf M. Huber, J. Marc Pipas, Maurice Pérol, Sergio Santillana
Publikováno v:
Journal of Clinical Oncology. 37:9036-9036
9036 Background: Seribantumab (MM-121) is a human monoclonal IgG2 antibody that blocks the HRG domain of HER3. Preclinical data suggest that seribantumab reverses HRG mediated drug resistance across multiple cancer models. In prior retrospective anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3270c7efc5024faa88a49e0be068ada
https://doi.org/10.1200/jco.2019.37.15_suppl.9036
https://doi.org/10.1200/jco.2019.37.15_suppl.9036